Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Christoph M, Griessinger"'
Autor:
Cristina Barca, Christoph M. Griessinger, Andreas Faust, Dominic Depke, Markus Essler, Albert D. Windhorst, Nick Devoogdt, Kevin M. Brindle, Michael Schäfers, Bastian Zinnhardt, Andreas H. Jacobs
Publikováno v:
Pharmaceuticals, Vol 15, Iss 1, p 13 (2021)
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis,
Externí odkaz:
https://doaj.org/article/f7390c051db04376bea368105001346a
Autor:
Martin Thunemann, Barbara F. Schörg, Susanne Feil, Yun Lin, Jakob Voelkl, Matthias Golla, Angelos Vachaviolos, Ursula Kohlhofer, Leticia Quintanilla-Martinez, Marcus Olbrich, Walter Ehrlichmann, Gerald Reischl, Christoph M. Griessinger, Harald F. Langer, Meinrad Gawaz, Florian Lang, Michael Schäfers, Manfred Kneilling, Bernd J. Pichler, Robert Feil
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
Non-invasive cell tracking is a powerful method to visualize cells in vivo under physiological and pathophysiological conditions. Here Thunemann et al. generate a mouse model for in vivo tracking and quantification of specific cell types by combining
Externí odkaz:
https://doaj.org/article/f6168d6482b4443e8fee432ca8cba8f0
Autor:
Ivonne-Aidee Montes-Mojarro, Julia Steinhilber, Christoph M. Griessinger, Achim Rau, Ann-Kathrin Gersmann, Ursula Kohlhofer, Petra Fallier-Becker, Huan-Chang Liang, Ute Hofmann, Mathias Haag, Wolfram Klapper, Elke Schaeffeler, Bernd J. Pichler, Matthias Schwab, Falko Fend, Irina Bonzheim, Leticia Quintanilla-Martinez
Publikováno v:
Leukemia. 36:2050-2063
We recently reported that miR-146a is differentially expressed in ALK+ and ALK− anaplastic large cell lymphoma (ALCL). In this study, the downstream targets of miR-146a in ALK+ ALCL were investigated by transcriptome analysis, identifying CD147 as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5e36340012771261e739b1ce2063e3
https://doi.org/10.1038/s41375-022-01617-x
https://doi.org/10.1038/s41375-022-01617-x
Autor:
Jean J.L. Tessier, Christian Klein, Jean Gudas, Ian A. Wilson, Dominik Rüttinger, Pablo Umana, Marina Bacac, Peter Brünker, Claudia Ferrara, Christina Claus, Johannes Sam, Valeria G. Nicolini, Marine Richard, Preethi L.B. Mohan, Maria Amann, Mudita Pincha, Tapan K. Nayak, Green Zhang, Chenyu Lee, Daulet Satpayev, Filippo Marchioni, Jason M. Romero, Michael Torgov, Fang Jia, Charles Zamilpa, Ziyue Karen Jiang, Alessandro Mascioni, Tove Olafsen, Christoph M. Griessinger
Figure S6 shows the correlation of CD8-IHC and tumoruptake as determined by gamma-counting or PET.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e6a13fe28eabcec76522fa717e14224
https://doi.org/10.1158/0008-5472.22425051.v1
https://doi.org/10.1158/0008-5472.22425051.v1
Autor:
Jean J.L. Tessier, Christian Klein, Jean Gudas, Ian A. Wilson, Dominik Rüttinger, Pablo Umana, Marina Bacac, Peter Brünker, Claudia Ferrara, Christina Claus, Johannes Sam, Valeria G. Nicolini, Marine Richard, Preethi L.B. Mohan, Maria Amann, Mudita Pincha, Tapan K. Nayak, Green Zhang, Chenyu Lee, Daulet Satpayev, Filippo Marchioni, Jason M. Romero, Michael Torgov, Fang Jia, Charles Zamilpa, Ziyue Karen Jiang, Alessandro Mascioni, Tove Olafsen, Christoph M. Griessinger
CD8-expressing T cells are the main effector cells in cancer immunotherapy. Treatment-induced changes in intratumoral CD8+ T cells may represent a biomarker to identify patients responding to cancer immunotherapy. Here, we have used a 89Zr-radiolabel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f178a6cff9e64f039bd22cb7364792b
https://doi.org/10.1158/0008-5472.c.6511935.v1
https://doi.org/10.1158/0008-5472.c.6511935.v1
Autor:
Jean J.L. Tessier, Christian Klein, Jean Gudas, Ian A. Wilson, Dominik Rüttinger, Pablo Umana, Marina Bacac, Peter Brünker, Claudia Ferrara, Christina Claus, Johannes Sam, Valeria G. Nicolini, Marine Richard, Preethi L.B. Mohan, Maria Amann, Mudita Pincha, Tapan K. Nayak, Green Zhang, Chenyu Lee, Daulet Satpayev, Filippo Marchioni, Jason M. Romero, Michael Torgov, Fang Jia, Charles Zamilpa, Ziyue Karen Jiang, Alessandro Mascioni, Tove Olafsen, Christoph M. Griessinger
Supplementary Material and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125a069e0ac29cf2a409ad1674f98503
https://doi.org/10.1158/0008-5472.22425048
https://doi.org/10.1158/0008-5472.22425048
Autor:
Martin Hutchings, Annika Loft, Wendy Osborne, George Petrides, Fritz Offner, Ciel De Vriendt, Giuseppe Gritti, Roberto Boni, William Townsend, Irfan Kayani, Ian Wilson, Yanjie Wang, Maria Jadhav, Cristina Santini, Claire Kelly, Martin Kornacker, Jean J.L. Tessier, Ann-Marie E Bröske, Angelika Lahr, Axel Boehnke, Christoph M. Griessinger
Publikováno v:
Blood. 140:10733-10735
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96a505396ab3f2e484c0abe781228a95
https://doi.org/10.1182/blood-2022-158154
https://doi.org/10.1182/blood-2022-158154
Autor:
Jaclyn Sceneay, Christoph M Griessinger, Sabrina H L Hoffmann, Shu Wen Wen, Christina S F Wong, Sophie Krumeich, Manfred Kneilling, Bernd J Pichler, Andreas Möller
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0196040 (2018)
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid progenitor cells that are expanded in cancer and act as potent suppressors of the anti-tumor immune response. MDSCs consist of two major subsets, namely monoc
Externí odkaz:
https://doaj.org/article/f903317873e640e2b381237398744b27
Autor:
Manfred Kneilling, Dominik Sonanini, Philipp Knopf, Barbara F. Schörg, Christoph M. Griessinger, Klaus Dittmann, Martin Röcken, Bernd J. Pichler
Publikováno v:
Theranostics
CD4+ T helper cells are capable of mediating long-term antitumoral immune responses. We developed a combined immunotherapy (COMBO) using tumor antigen-specific T helper 1 cells (Tag-Th1), dual PD-L1/LAG-3 immune checkpoint blockade, and a low-dose to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3162d97489dd42e543ca5f5e6ddb88df
http://europepmc.org/articles/PMC8315067
http://europepmc.org/articles/PMC8315067
Autor:
Marine Richard, Jason Romero, Daulet Satpayev, Peter Brünker, Filippo Marchioni, Mudita Pincha, Tapan K. Nayak, Pablo Umana, Nicolini Valeria G, Claudia Ferrara, Marina Bacac, Maria Amann, Christoph M. Griessinger, Fang Jia, Charles Zamilpa, Michael Torgov, Christian Klein, Tove Olafsen, Jean Tessier, Dominik Rüttinger, Alessandro Mascioni, Christina Claus, Ian Andrew Wilson, Jean Gudas, Johannes Sam, Preethi Latha Bhavani Mohan, Ziyue Karen Jiang, Green Zhang, Chenyu Lee
Publikováno v:
Cancer Research. 80:2903-2913
CD8-expressing T cells are the main effector cells in cancer immunotherapy. Treatment-induced changes in intratumoral CD8+ T cells may represent a biomarker to identify patients responding to cancer immunotherapy. Here, we have used a 89Zr-radiolabel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc77094c3b0b3f652e7fc1b51864a2c4
https://doi.org/10.1158/0008-5472.can-19-3269
https://doi.org/10.1158/0008-5472.can-19-3269